Annovis Reveals New Biomarker Findings in Alzheimer’s Patients Highlighting Buntanetap’s Promise as a Disease-Modifying Therapy

Buntanetap's Efficacy: Annovis Bio announced promising results from its Phase 2/3 study of buntanetap, showing its ability to reduce inflammation and improve cellular health in Alzheimer's patients, suggesting potential disease-modifying effects.

Biomarker Analysis: The treatment group exhibited reduced levels of inflammatory markers and improved neuronal health, particularly in patients with positive pTau217 plasma levels, reinforcing the drug's multifaceted approach to tackling Alzheimer's disease.

Ongoing Research: Buntanetap is currently being evaluated in a pivotal Phase 3 trial focused on early Alzheimer's, with results expected in 6 and 18 months to assess both symptomatic improvement and disease modification.

Future Presentations: Full biomarker data will be presented at the Clinical Trials on Alzheimer's Disease conference in December 2025, with further details to be announced closer to the event.